^
    Back
    Association details:
    Biomarker:HLA-A*03
    Cancer:Solid Tumor
    Drug Class:PD1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    New
    Source:
    Lancet
    Title:

    HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

    Published date:
    01/01/2022
    Excerpt:
    HLA-A*03 was associated in an additive manner with reduced overall survival after ICI treatment in the MSK-IMPACT cohort (HR 1·48 per HLA-A*03 allele [95% CI 1·20–1·82], p=0·00022), the validation DFCI Profile cohort (HR 1·22 per HLA-A*03 allele, 1·05–1·42; p=0·0097), and in the JAVELIN Solid Tumour clinical trial for bladder cancer (HR 1·36 per HLA-A*03 allele, 1·01–1·85; p=0·047).
    DOI:
    10.1016/S1470-2045(21)00582-9